Position in ALMS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$6,825,019
-$800,246 QoQ
Shares Held
242,538
-29.9% QoQ
Ownership
0.187%
of shares outstanding
% of Portfolio
0.14%
of 13F equity value
Holder Rank
#52
of 199 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 0%
Shared 100%
None 0%
Common Shares in ALMS Over Time
Shares Held
Position Value (USD)
Derivatives in ALMS
reported options exposure · as of Jun 30, 2026CallValue
$2,943,444
CallShares
104,600
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026BOOTHBAY FUND MANAGEMENT, LLC holds $666,641,771 across 159 Biotechnology names. ALMS ranks #20 (1.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RVMD |
Revolution Medicines, Inc.
|
465,787 | $87,232,589 | |
| 2 | ABVX |
Abivax S.A.
|
563,367 | $75,074,286 | |
| 3 | EXEL |
Exelixis, Inc.
|
804,095 | $43,750,808 | |
| 4 | PCVX |
Vaxcyte, Inc.
|
534,163 | $31,050,895 | |
| 5 | COGT |
Cogent Biosciences, Inc.
|
692,825 | $26,812,327 | |
| 6 | CGEM |
Cullinan Therapeutics, Inc.
|
1,082,611 | $19,714,346 | |
| 7 | TNGX |
Tango Therapeutics, Inc.
|
500,497 | $15,645,536 | |
| 8 | AVTX |
Avalo Therapeutics, Inc.
|
702,051 | $12,973,902 |
All Filings in ALMS
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,943,444 | 104,600 | Call | Other | 2026-08-14 | |
| 2026-06-30 | $6,825,019 | 242,538 | Shares | Other | 2026-08-14 | |
| 2026-03-31 | $7,625,265 | 346,131 | Shares | Other | 2026-05-15 | |
| 2026-03-31 | $1,698,513 | 77,100 | Call | Other | 2026-05-15 | |
| 2025-12-31 | $566,080 | 58,000 | Put | Other | 2026-02-17 | |
| No filing history on record for this holder in this stock. | ||||||